

Can Nutritional Supplementation Increase the Risk of Crizotinib-Associated Hepatotoxicity: A Clinical Case Example

Y. Zenzri, N. Daoud, H.El Benna, Y. Berrazaga, and H. Boussen

Medical oncology department. Abderrahmen Mami Hospital. Ariana, Tunisia.

Corresponding Author: Y.Zenzri Medical oncology department. Abderrahmen Mami Hospital. Ariana,Tunisia E-mail:yosr-zenzri@live.fr

Received Date: October 16, 2020; **Accepted Date:** November 30, 2020; **Published Date:** November 20, 2020.

Citation: Zenzri Y, Importance from the postgraduate upping in financial administration subjects for health educational managers.Review Article *J. Clin Case Rep and Stud.* 1(7). Doi: [10.31579/2690-8808/048](https://doi.org/10.31579/2690-8808/048)

Copyright: © 2020 Zenzri Y, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract:

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. The identification of oncogenetic driver mutation in lung cancer led to a therapeutic revolution by the discovery of targetable genetic alterations including the anaplastic lymphoma kinase (ALK) fusion oncogene and ROS1 . The tyrosine kinase inhibitor “Crizotinib” improved clinical outcome and prolonged responses. Severe hepatotoxicity is a rare adverse event .We report a case of Crizotinib-induced acute hepatitis with a probable drug-bergamot interaction.

Key words: crizotinib; bergamot; hepatotoxicity

Introduction:

Crizotinib is a targeted therapy, tyrosine kinase inhibitor that proved its efficacy in advanced non-small cell lung cancer (NSCLC). At a conventional oral dose of 250 mg, twice daily, it is well-tolerated and the most frequently occurring adverse events graded 1, 2 are visual disorders, gastrointestinal symptoms (diarrhea, nausea-vomiting, anorexia, constipation) ,peripheral edema and neutropenia [1]. The mechanism of Crizotinib hepatotoxicity is unknown. Grade 3-4 liver toxicity is an unusual side effect. We present here a case of Crizotinib-induced severe hepatotoxicity.

Case presentation:

A 61-year-old non smoker woman, without medical comorbidities or hepatic previous disease, presents with a 4-months history of isolated dry cough. Physical examination was normal. Etiological work-up showed the presence on CT-scan of a bulky right lung lesion, with contralateral axillary and supraclavicular lymph nodes with right pleural effusion. Bronchoscopy showed tumor localized to right upper lobar bronchus and biopsies have concluded a primary lung adenocarcinoma with positive TTF1 on immunohistochemistry(IHC). We performed a screening for anaplastic lymphoma kinase(ALK) , epidermal growth factor receptor(EGFR) and ROS 1. *ROS1 rearrangement was identified.* Additional work-up showed the presence on brain magnetic resonance imaging (MRI) of cerebral, bone and lymph nodes metastases. She was diagnosed with stage IV lung cancer in February 2019.The patient's full blood count, renal and liver function tests were normal .The patient was started on tablet Crizotinib 250 mg twice per day ten days after diagnosis. Crizotinib was given as monotherapy for front line management. During the follow-up, 53 days after the beginning of Crizotinib, she presented to the emergency department with complaints of fatigue, vomiting, anorexia and nausea since 2 days. The clinical examination was normal. There was neither hepatomegaly nor jaundice. A complete blood count, kidney and

liver tests were performed. Liver tests showed highly increased ALT at 2413 IU/l (45 * times the upper limit of normal), AST at 1062 IU/l (20* times the upper limit of normal), prothrombine time (PT) at 62%, while ALP, GGT and bilirubin were normal. She was admitted to the hospitalist team for management of acute hepatitis. An abdominal ultrasound was normal for liver parenchyma and bile ducts without obstruction or ischemic hepatitis.

Hepatitis B markers were negative for HBs Antigen and HBc antibodies as well as PCR testing for HCV, cytomegalovirus, herpes simplex virus and Epstein–Barr virus. The patient reported having consumed Bergamot orange during Crizotinib treatment. We decided to stop the treatment and the bergamot intake .One month after livers tests normalization, we decided to restart it at a half dose of 250 mg once daily. However, 2 days after drug reintroduction, liver tests showed hepatic cytolysis and we stopped definitely Crizotinib.

Ceritinib was the second-line drug received during three months. Treatment was started at

a dose of 750 mg/day. Regular liver enzyme testing was carried out during treatment. The tests were normal. A progression of the disease was noted after 3 months of Ceritinib. The patient is on third line chemotherapy by pemetrexed and carboplatin.

Discussion:

This report describes a durg –induced acute hepatitis by Crizotinib , a small molecule inhibitor with multiple targets, including *ALK*, *c-MET*, and *ROS1*. Crizotinib is approved for the treatment of a distinct subgroup of NSCLC mediated by rearrangements of ALK or ROS1 [2, 3]. The PROFILE 1 and subsequent randomized studies proved Crizotinib efficacy ,safety and its superiority compared with chemotherapy. The most common adverse events of Crizotinib include diarrhea, constipation, abdominal pain, anorexia, nausea, visual disturbances, fatigue and

peripheral edema. Potentially serious adverse effects include interstitial lung disease and QT prolongation [4]. In a recent meta-analysis about 1,908 patients from 10 clinical trials, ALT and AST all-grades increase were observed in 25.2 and 26%, respectively, while grade 3 and 4 were reported in 7 and 9.9%. Sub-group analysis showed a higher incidence of liver toxicities for ceritinib compared to Crizotinib and alectinib [5].

Ripault et al reported the first case with crizotinib-induced acute hepatitis, who relapsed after reintroduction of the treatment [6]. Profile 1014, a phase 3 study has demonstrated that grade 3 or 4 elevated aminotransferases were noted in 24 patients receiving Crizotinib [4]. A majority of these adverse events were reversible on dose interruption. Four cases of fatal hepatic failure have been reported in the literature (table 1).

Authors	Dose of Crizotinib	Therapy line	Occurrence time of fulminant liver failure
Sato [7]	400 mg every day	First line	Day 29
Van Geel [8]	250 mg twice a day	Second line	Day 24
Adhikari [9]	250 mg twice a day	First line	Day 39
Zhang [10]	250 mg twice a day	First line	Day 46

Table 1: Case reports of Crizotinib-induced fatal hepatic failure

The mechanism of crizotinib-induced hepatotoxicity remains unknown. Yasuda et al suggested that the underlying mechanism was partly an allergic reaction to Crizotinib or its metabolites. Dose reduction associated with oral steroids following crizotinib-induced hepatotoxicity did not improve the hepatitis. Oral desensitization may be considered as a good option following hepatitis [11]. Moreover, Ceritinib which is a small molecule tyrosine kinase receptor inhibitor could be an alternative treatment when crizotinib causes hepatotoxicity [12]. Specific risk factors for Crizotinib-induced hepatitis remain unclear. General risk factors of drug-induced hepatotoxicity are reported to be female sex, pregnancy, older age, excessive alcohol intake, smoking, HBV or HCV infection, HIV infection and genetic variability [13,14].

The use of CYP3A inducers and inhibitors like grapefruit juice must be interrupted since it may increase the plasma concentration of Crizotinib [15]. In our case, the patient reported having consumed Bergamot orange during treatment. Bergamottin is a natural furanocoumarin found in the pulp of pomelos and grapefruits. It is also found in the peel and pulp of the bergamot orange. Bergamottin was tested for its inhibitory effects on hydroxylase and O-dealkylase activities of human cytochrome P450 isoenzymes CYP 3A4 and CYP 1B1 [16]. This could explain the enhancement of liver toxicity observed in our patient.

Crizotinib-induced hepatotoxicity usually occurs within the first two months of treatment. Monitoring liver function tests every two weeks is mandatory during this period. A thorough knowledge of the metabolism and pharmacologic properties of the treatment is important to prevent side effects.

Conclusion:

Although Crizotinib is usually well tolerated, it can cause acute hepatitis in lung cancer patient. Regular liver enzyme testing should be carried out during the first two months of Crizotinib treatment. Further work should explore underlying mechanisms of these severe cases to identify risk factors that can induce hepatotoxicity.

Authors contribution :

Concepts: Nouha Daoud, Yosr Zenzri

Design: Hamouda Boussen, Nouha Daoud, Yosr Zenzri

Definition of intellectual content: Hamouda Boussen, Nouha Daoud, Yosr Zenzri, Houda El Benna

Literature search: Yosr Zenzri, Nouha Daoud

Manuscript preparation: Nouha Daoud, Yosr Zenzri, Houda El Benna

Manuscript editing: Yosr Zenzri, Nouha Daoud

Manuscript review: Yosr Zenzri, Nouha Daoud, Houda El Benna, Yosra Berrazaga

Guarantor: Hamouda Boussen, Yosr Zenzri, Nouha Daoud

Funding: Not applicable

Conflicts of interest: The authors declare that they have no conflicts of interest.

Acknowledgments : None

References:

1. Arbour K.C, Riely G.J. (2017). Diagnosis and treatment of ALK positive NSCLC. *Hematol Oncol Clin North Am*; 31:101-11
2. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med.*; 363: 1693-1703
3. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, et al. (2015). Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med.*; 371: 1963-1971
4. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med.*; 371: 2167-2177
5. Liu B, Yuan M, Sun Y, Cheng Z, Zhang Z, et al. (2018). Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. *Oncotarget.*; 9: 9480-9488
6. Ripault MP, Pinzani V, Fayolle V. (2013). Crizotinib-induced acute hepatitis: First case with relapse after reintroduction with reduced dose. *Clin Res Hepa Gastroenterol* ; 37: e21-23
7. Sato Y, Fujimoto D, Shibata Y, Seo R, Sugino Y, et al. (2014). Fulminant Hepatitis Following Crizotinib Administration for ALK-positive Non-small-cell Lung Carcinoma. *Jpn J Clin Oncol.*; 44 :872-875
8. Van Geel RM, Hendriks JJ, Vahl JE, Van Leerdam ME, Van den Broek D, et al. (2016). Crizotinib-induced fatal fulminant liver failure. *Lung Cancer.*; 93: 17-19
9. Adhikari N, Kumar P, Venkatesulu BP, Pandey R, Haresh KP, et al. (2018). Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event. *J Glob Oncol.*; 4: 1-4
10. Zhang Y, Xu YY, Chen Y, Li JN, Wang Y. (2019). Crizotinib-induced acute fatal liver failure in an Asian ALK-positive lung

- adenocarcinoma patient with liver metastasis: A case report. *World J Clin Cases.*; 7: 1080–1086
11. Yasuda Y, Nishikawa Y, Sakamori Y, Terao M, Hashimoto K, et al. (2017). Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. *Mol Clin Oncol.*; 7: 295–297
 12. Sassier M, Mennecier B, Gschwend A, Rein M, Coquerel A, et al. (2016). Successful treatment with ceritinib after crizotinib induced hepatitis. *Lung Cancer.*; 95: 15-16
 13. Kazuto Tajiri, Yukihiro Shimizu. (2008). Practical guidelines for diagnosis and early management of drug-induced liver injury. *World J Gastroenterol*; 14: 6774–6785
 14. Bell LN, Chalasani N. (2009). Epidemiology of idiosyncratic drug-induced liver injury. *Semin Liver Dis.*; 29: 337-347
 15. Curran MP. (2012). Crizotinib: in locally advanced or metastatic non-small cell lung cancer. *Drugs. Europe PMC*; 72: 99-107
 16. Girenavar B, Poulouse SM, Jayaprakasha GK, Bhat NG, Patil BS. (2006). Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes. *Bio org Med Chem.*; 14: 2606-2612